Notably, a multi-center Phase I clinical trial (NCT04623944, Table 1) is currently assessing allogeneic CAR-NK cells targeting NKG2D ligands, in the presence or absence of the DNMT inhibitor Decitabine, in patients with R/R AML and myelodysplastic syndrome (MDS). Here, DNMT1 is linked to myelodysplastic syndrome.